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In their Letter to the Editor, Drs. F. 
Macbeth and T. Treasure refer to two 
articles published in the October 2014 
issue of Journal of Thoracic Oncology 
related to treatment of lung metasta-
ses.1–3 They correctly point out that there 
are no large randomized trials to provide 
a definite proof that resection of lung 
metastases prolongs survival in patients. 
They even take it one step back and pro-
pose to obtain level I evidence before 
performing further studies. In this 
regard, they could have chosen many 
surgical papers that were recently pub-
lished in Journal of Thoracic Oncology. 
For most thoracic surgical procedures 
there is no such evidence to support 
them. This relates to surgery for medi-
astinal tumors as thymoma, mesotheli-
oma, locally advanced lung cancer, and 
even early stage lung cancer! Does this 
mean that surgery is not a valid treat-
ment, as the authors seem to suggest? 
How to approach individual patients 
when there is lack of level I evidence? 
Although not very clearly, the authors 
suggest that we should not continue 
any treatment modality until this evi-
dence becomes available. However, they 
have not proven the reverse statement: 
“absence of evidence” does not mean 
“evidence of absence” as indicated in 
several editorials.4 They state that “there 
is reason to believe that any perceived 
survival benefit may simply be because 
of patient selection.” This is not a very 
scientific statement and not a single ref-
erence is mentioned to support this.
Surgery became an accepted 
treatment for many tumors as it pro-
vides the opportunity to completely 
remove the primary tumor and drain-
ing lymph nodes although no formal 
comparison with conservative treat-
ment is available. For this reason, there 
is an inherent problem when proposing 
randomized trials comparing surgery 
to conservative management which 
is often perceived as treatment with-
drawal. Even when randomized trials 
are performed, there is still no absolute 
truth and a certain degree of uncer-
tainty remains.4 Moreover, the con-
clusions are only valid for the study 
population for which strict inclusion 
and exclusion criteria were designed. 
For rare tumors as mesotheliomas 
and thymomas it will never be pos-





Absence of Evidence 
is not Evidence of 
Absence!
Secondly, there is a report of the 
use of whole lung perfusion after pul-
monary metastasectomy for colorectal 
cancer or sarcoma.2 This starts by saying 
that the prognosis of these patients has 
not changed in 20 years, but their conclu-
sion is not that perhaps metastasectomy 
does not make a difference, but seems 
to be “we need to do something more.” 
They report the use a toxic drug without 
a good track record in either tumor to 
perfuse the whole lung and that 44% of 
patients experienced grade 3 or 4 toxicity. 
Although there was an apparent reduction 
in pulmonary metastases there seemed to 
be no improvement in time to progres-
sion or overall survival—compared with 
historical series.
There is an increasingly embedded 
view that pulmonary metastasectomy is 
a proven and effective surgical treatment 
that improves patient outcomes and so 
now people are investigating less inva-
sive techniques (e.g., stereotactic abla-
tive radiotherapy and radiofrequency 
ablation) or, adding locally perfused 
chemotherapy. Both papers cite the 1997 
publication of International Registry on 
Lung Metastasis3 which was a landmark 
in pooling uncontrolled data, permitting 
analysis of over 5000 cases. But it contains 
no evidence on what might have been the 
survival among similarly selected patients 
without metastasectomy—there were no 
controls and that remains the case.4
Not only are the patients having 
metastasectomy highly selected but so 
too are citations in the publication.5 
Pulmonary metastasectomy is a good 
example of how selective citation and 
repeated authoritative publication can 
create “facts” from hypotheses. There is 
no randomized trial evidence to support 
the belief that it is an effective inter-
vention and there is reason to believe 
that any perceived survival benefit may 
simply be because of patient selection. 
This is an insecure foundation of which 
to justify ablative therapies.6 Before 
embarking on more, uncontrolled 
research into “better” ways of remov-
ing pulmonary metastases, there need 
to be well-conducted randomized trials 
investigating the value of the procedure.
Fergus Macbeth, DM, FRCR, FRCP
Wales Cancer Trials Unit
Cardiff University
Cardiff, UK 
Tom Treasure, MD, FRCS
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controlled trial and well-designed pro-
spective registries as created by the 
International Association for the Study 
of Lung Cancer and the International 
Thymic Malignancies Interest Group 
will provide valuable information to 
advance the field and give a profound 
insight in these tumors.
Although the authors state that 
we used a “toxic drug without a good 
track record” it should be emphasized 
that, before embarking on a multicenter 
phase II study, extensive experimen-
tal work on isolated lung perfusion 
was performed followed by a phase I 
study to determine dose-limiting tox-
icity.5 The main question in our study 
was not whether surgery in this setting 
is better than conservative treatment, 
which in fact was clearly proven in 
our experimental studies, but whether 
the objective results of surgery can be 
improved by combined modality ther-
apy, a point not raised by the authors.
Although results of large random-
ized controlled trials are currently lack-
ing for many surgical procedures, this 
does not mean that therapeutic nihilism 
should prevail. As the authors provide 
no convincing proof of the absence of 
any effect of surgical therapy in tho-
racic oncology, the final answer is still 
blowing in the wind and related burning 
questions, explored in well-designed 
experimental and clinically relevant 
studies should not be put on hold.
Paul E. Van Schil
Department of Thoracic and 
Vascular Surgery
Antwerp University Hospital
Edegem, Antwerp, Belgium 
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